Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Management of R/R myeloma and MRD assessment

Elena Zamagni • 10 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Bortezomib CAR-T Carfilzomib Daratumumab Dexamethasone Elotuzumab Isatuximab Lenalidomide Pomalidomide

Elena Zamagni, MD, PhD, of the University of Bologna, Bologna, Italy, outlines the management of relapsed/refractory (R/R) multiple myeloma and measurable residual disease (MRD) assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Elena Zamagni

A project to improve the understanding of disease biology and treatment outcomes in myeloma 1:34
A project to improve the understanding of disease biology and treatment outcomes in myeloma
Elena Zamagni • 9 Dec 2024
SRI results from MajesTEC-4: Tec-Len or Tec alone as maintenance therapy in newly diagnosed myeloma 1:39
SRI results from MajesTEC-4: Tec-Len or Tec alone as maintenance therapy in newly diagnosed myeloma
Elena Zamagni • 9 Dec 2024
The future of myeloma: the potential role of MRD-driven therapy de-escalation strategies 0:57
The future of myeloma: the potential role of MRD-driven therapy de-escalation strategies
Elena Zamagni • 9 Dec 2024
Patient selection for selinexor 0:35
Patient selection for selinexor
Elena Zamagni • 24 Oct 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals